tbuckley/cabot-search huggingface dataset:
Baseline computed tomography screening and blood microRNA predict lung cancer risk and define adequate intervals in the BioMILD trial
Authors: U. Pastorino, M. Boeri, S. Sestini, F. Sabia, G. Milanese, M. Silva, P. Suatoni, C. Verri, A. Cantarutti, N. Sverzellati, G. Corrao, A. Marchianò, G. Sozzi
Journal: Annals of Oncology (2022)

Large randomized trials have demonstrated that lung cancer (LC) screening with low-dose computed tomography (LDCT) reduces LC mortality in heavy smokers. We previously showed in the MILD screening trial that the combination of a prespecified circulating microRNA (miRNA) signature classifier (MSC) and LDCT improves the accuracy of LDCT alone. The primary aim of the prospective BioMILD study was to assess the additional value of the blood MSC assay at the time of baseline LDCT with the goal of personalizing LC screening intervals.The study enrolled 4119 volunteers from January 2013 to March 2016, with a median follow-up of 5.3 years. Baseline LDCT and miRNAs stratified participants into four groups: CT-/MSC- (n = 2664; 64.7%); CT-/MSC+ (n = 800; 19.4%); CT+/MSC- (n = 446; 10.8%); and CT+/MSC+ (n = 209; 5.1%). As per the protocol, those in the CT-/MSC- and CT-/MSC+ groups were allocated to LDCT repeat at 3-year and 1-year intervals; CT+ participants were allocated for 1-year or earlier intervals on the basis of LDCT features independent of MSC results.CT+ participants had a 15.8-fold higher 4-year LC incidence than CT- participants (95% confidence interval 10.34-24.05), and MSC+ participants had a 2.0-fold higher 4-year LC incidence than MSC- participants (95% confidence interval 1.40-2.90); there was no evidence that the MSC effect differed between CT+ and CT- participants. LC incidence at 4 years was 0.8% in CT-/MSC-, 1.1% in CT-/MSC+, 10.8% in CT+/MSC-, and 20.1% in CT+/MSC+ participants. LC mortality rates at 5 years in the four risk groups were 0.5 in CT-/MSC-, 1.5 in CT-/MSC+, 4.2 in CT+/MSC-, and 10.1 in CT+/MSC+.The combined use of LDCT and blood miRNAs at baseline predicts individual LC incidence and mortality, with a major effect of MSC for LDCT-positive individuals. These findings may have important implications in personalizing screening intervals.
Mellon Issues Beer Regulations
Journal: JAMA (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Risk Factors for Diabetic Peripheral Neuropathy in Adolescents and Young Adults With Type 2 Diabetes: Results From the TODAY Study
Authors: Lorraine E. Levitt Katz, Neil H. White, Laure El ghormli, Christine L. Chan, Kenneth C. Copeland, Terri H. Lipman, Marsha D. Marcus, Philip Zeitler
Journal: Diabetes Care (2021)

OBJECTIVE Data related to diabetic neuropathy in youth with type 2 diabetes are limited. We examined the relationship of glycemic control, sex, race/ethnicity, BMI, and other type 2 diabetes-associated factors with the development of diabetic peripheral neuropathy (DPN) in youth with type 2 diabetes enrolled in the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) study. RESEARCH DESIGN AND METHODS The Michigan Neuropathy Screening Instrument (MNSI) and a 10-g monofilament exam were performed annually. DPN was defined as a score (&amp;gt;2) on the MNSI-exam or combined MNSI-exam and MNSI-survey scores (exam &amp;gt;2 and/or survey ≥4), or monofilament exam (&amp;lt;8 of 10 correct responses) at two or more consecutive visits. Multivariable time-to-event models assessed the association of risk factors evaluated longitudinally with DPN events. RESULTS A total of 674 participants (35% male), with a mean age of 14 years and diabetes duration &amp;lt;2 years at study entry, were evaluated annually over an average of 10.2 years. Male subjects had a significantly higher cumulative incidence of DPN than female subjects (38.5% vs. 27.2% via MNSI-exam, P = 0.002; 14.0% vs. 5.1% via monofilament exam, P = 0.01). Rates did not differ by race/ethnicity. Higher HbA1c and BMI were associated with higher DPN, by both MNSI and the monofilament test. In multivariable models, male sex, older age, and higher BMI were associated with MNSI-exam DPN risk. CONCLUSIONS DPN was evident early in the course of youth-onset type 2 diabetes and increased over time. It was higher in male subjects and related to glycemic control. These findings raise concern for long-term development of neuropathy-related morbidity in youth with type 2 diabetes and the need to achieve improved glycemic control.
Clinical Outcomes in Patients With Delayed Hospitalization for Non–ST-Segment Elevation Myocardial Infarction
Authors: Jung-Joon Cha, SungA Bae, Duk-Woo Park, Jae Hyoung Park, Soon Jun Hong, Seong-Mi Park, Cheol Woong Yu, Seung-Woon Rha, Do-Sun Lim, Soon Yong Suh, Seung Hwan Han, Seong-Ill Woo, Nae-Hee Lee, Donghoon Choi, In-Ho Chae, Hyo-Soo Kim, Young Joon Hong, Youngkeun Ahn, Myung Ho Jeong, Tae Hoon Ahn
Journal: Journal of the American College of Cardiology (2022)
A Single Arm, Phase II Study of Eltrombopag to Enhance Platelet Count Recovery in Older Patients with Acute Myeloid Leukemia Undergoing Remission Induction Therapy
Authors: Sudipto Mukherjee, Paul Elson, Samjhana Bogati, Ashley Woltman, John Desamito, Aaron T. Gerds, Hetty E. Carraway, Anjali S. Advani, Yogen Saunthararajah, Jaroslaw P Maciejewski, Matt Kalaycio, Mikkael A. Sekeres
Journal: Blood (2016)
Percutaneous image guided cryoablation and radio-frequency ablation versus partial nephrectomy for small renal cell carcinomas: A ten-years, single centre observational study
Authors: V.W-S. Chan, F.H. Osman, J. Cartledge, M. Kimuli, N. Vasudev, C. Ralph, S. Jagdev, S. Bhattarai, J. Smith, J. Lenton, T.M. Wah
Journal: European Urology (2021)
A randomized trial regarding Antimicrobial Prophylaxis (AMP) in Transurethral Resection of Bladder tumor (TURB) in support of antimicrobial stewardship
Authors: E. Baten, F. Van Der Aa, H. Goethuys, K. Slabbaert, I. Arijs, K. Van Renterghem
Journal: European Urology (2021)
School Learning Format and Children’s Behavioral Health During the COVID-19 Pandemic
Authors: Emily C. Hanno, Lily S. Fritz, Stephanie M. Jones, Nonie K. Lesaux
Journal: JAMA Pediatrics (2022)

The COVID-19 pandemic has interrupted the education of more than 1 billion children worldwide, with many experiencing shifts between remote, hybrid, and in-person learning. 1 As the COVID-19 pandemic and interruptions to learning continue, we need to understand their consequences for children's behavioral health to inform response efforts.We used longitudinal data to examine how children's behavioral well-being differed by learning format.
TCTAP A-068 Impact of Percutaneous Coronary Intervention for Chronic Total Occlusion Patients with Near-normal Left Ventricular Function
Authors: Li Hu, Seung-Woon Rha, Byoung Geol Choi, Se Yeon Choi, Jae Kyeong Byun, Min Shim, Jun Hyuk Kang, Woo Hyeun Kim, Sung Hun Park, Eun Jin Park, Jah Yeon Choi, Sunki Lee, Jin Oh Na, Cheolung Choi, Hong Euy Lim, Jin Won Kim, Eung Ju Kim, Chang Gyu Park, Hong Seog Seo, Dong Joo Oh
Journal: Journal of the American College of Cardiology (2017)
Clinical Challenge About Retinal Artery Thrombosis and Aortic Valve Vegetations
Authors: William A. Schiavone
Journal: JAMA (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies
Authors: Olivier Michielin, Aly-Khan Lalani, Caroline Robert, Padmanee Sharma, Solange Peters
Journal: Journal for ImmunoTherapy of Cancer (2022)

Introduction Immuno-oncology therapies, including immune checkpoint inhibitors (ICIs), have transformed cancer care and have brought into question whether classic oncology efficacy assessments adequately describe the distinctive responses observed with these agents. With more ICI-based therapies being approved across multiple tumor types, it is essential to define unique clinical hallmarks of these agents and their associated assessments to better reflect the therapeutic impact for both patients and physicians. Long-term survival and objective responses, such as depth and durability of responses, treatment-free survival, efficacy in brain metastases, improved health-related quality of life, and unique safety profiles, are among the hallmarks that have emerged for ICI therapies. An established clinical hallmark is a sustained long-term survival, as evidenced by a delayed separation of Kaplan-Meier survival curves, and a plateau at ~3 years. Combination ICI therapies provide the opportunity to raise this plateau, thereby affording durable survival benefits to more patients. Deepening of responses over time is a unique clinical ICI hallmark, with patients responding long term and with more durable complete responses. Depth of response has demonstrated prognostic value for long-term survival in some cancers, and several ICI studies have shown sustained responses even after discontinuing ICI therapy, offering the potential for treatment-free intervals. Although clinical evidence supporting efficacy in brain metastases is limited, favorable ICI intracranial responses have been seen that are largely concordant with extracranial responses. While patient outcomes can be significantly improved with ICIs, they are associated with unique immune-mediated adverse reactions (IMARs), including delayed ICI toxicities, and may require multidisciplinary management for optimal care. Interestingly, patients discontinuing ICIs for IMARs may maintain responses similar to patients who did not discontinue for an IMAR, whether they restarted ICI therapy or not. Conclusion Herein, we comprehensively review and refine the clinical hallmarks uniquely associated with ICI therapies, which not only will rejuvenate our assessment of ICI therapeutic outcomes but also will lead to a greater appreciation of the effectiveness of ICI therapies.
Effective Genome Editing Using CRISPR‐Cas9 Nanoflowers
Authors: Chen Zhang, He Ren, Gengqi Liu, Jiexin Li, Xiaojie Wang, Yumiao Zhang
Journal: Advanced Healthcare Materials (2022)

CRISPR-Cas9 as a powerful gene-editing tool has tremendous potential for the treatment of genetic diseases. Herein, a new mesoporous nanoflower (NF)-like delivery nanoplatform termed Cas9-NF is reported by crosslinking Cas9 and polymeric micelles that enables efficient intracellular delivery and controlled release of Cas9 in response to reductive microenvironment in tumor cells. The flower morphology is flexibly tunable by the protein concentration and different types of crosslinkers. Cas9 protein, embedded between polymeric micelles and protected by Cas9-NF, remains stable even under extreme pH conditions. Responsive cleavage of crosslinkers in tumor cells, leads to the traceless release of Cas9 for efficient gene knockout in nucleus. This crosslinked nanoparticle exhibits excellent capability of downregulating oncogene expression and inhibiting tumor growth in a murine tumor model. Taken together, these findings pave a new pathway toward the application of the protein-micelle crosslinked nanoflower for protein delivery, which warrants further investigations for gene regulation and cancer treatment.
Association of Ad26.COV2.S COVID-19 Vaccine With Presumptive Guillain-Barré Syndrome
Authors: Hai-Feng Li, Shi-Min Hu, Ming Lv
Journal: JAMA (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Immunogenicity and Safety of a Third SARS-CoV-2 Vaccine Dose in Patients With Multiple Sclerosis and Weak Immune Response After COVID-19 Vaccination
Authors: Marton König, Hilde Marie Torgauten, The Trung Tran, Trygve Holmøy, John Torgils Vaage, Fridtjof Lund-Johansen, Gro Owren Nygaard
Journal: JAMA Neurology (2022)
Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in <scp>DAPA‐HF</scp>
Authors: Kirsty McDowell, Paul Welsh, Kieran F. Docherty, David A. Morrow, Pardeep S. Jhund, Rudolf A. de Boer, Eileen O'Meara, Silvio E. Inzucchi, Lars Køber, Mikhail N. Kosiborod, Felipe A. Martinez, Piotr Ponikowski, Ann Hammarstedt, Anna Maria Langkilde, Mikaela Sjöstrand, Daniel Lindholm, Scott D. Solomon, Naveed Sattar, Marc S. Sabatine, John J.V. McMurray
Journal: European Journal of Heart Failure (2022)
Letter to the editor: Prospective study of stereotactic body radiation therapy for hepatocellular carcinoma on waitlist for liver transplant
Authors: Puja Sahai, Ankur Jindal, Amar Mukund
Journal: Hepatology (2022)

To the editor, We read with interest the study by Wong et al.[1] regarding stereotactic body radiation therapy (SBRT) for HCC on the waitlist for a liver transplant. We would like to make a note on the SBRT dose protocol followed in the study. In Table 2, the median with range of the dose is mentioned as 50 Gy (30–50). In another row of the same table, the dose to 95% of the planning target volume (PTV) is specified as 50.06 Gy (36.20–103.41). The researchers could state the median dose used in the study, which may have been between 35 and 50 Gy. The maximum point dose (Dmax) to the PTV needs to be specified as well. The mean dose to liver minus gross tumor volume (GTV) is mentioned as a median of 14.94 Gy (6.92–61.25) in Table 2. However, the RTOG 1112 protocol[2] that was followed for the study by Wong et al. limits the mean dose to 13.0–15.5 Gy for the respective prescription doses from 35 to 50 Gy. The median dose to 800 cc of liver minus GTV is specified as 1.5 Gy (0.16–16.94) in Table 2. Given that it is important to spare >700–800 cc of liver minus GTV or internal target volume (ITV), it may be worth mentioning about the volume that received a dose less than the specified limit. The volume of liver minus GTV or ITV that receives a dose <13.0–15.5 Gy needs to be ≥700–800 cc. The study by Wong et al.[1] included patients with Child Pugh A and B as compared to the inclusion of only Child Pugh A in the RTOG 1112 protocol. Therefore, the researchers could state whether different dose‐volume constraints for the liver were used for patients with Child Pugh class B. In addition, the dose constraints to a 0.5‐cc volume of organs at risk, as mentioned in the Supporting Information by Wong et al., are: 45 Gy to the esophagus, stomach, duodenum, and small bowel and 50 Gy to the large bowel. However, the RTOG 1112 protocol specifies the dose constraints to a 0.5‐cc volume as follows: 32 Gy to the esophagus and large bowel and 30 Gy to the stomach, duodenum, and small bowel. Furthermore, the dose constraint to the skin is not mentioned in the Supporting Information. CONFLICT OF INTEREST Nothing to report. AUTHOR CONTRIBUTIONS Puja Sahai, Ankur Jindal, and Amar Mukund substantial contributions to conception and design. Puja Sahai, Ankur Jindal, and Amar Mukund drafting the article or revising it critically for important intellectual content. Puja Sahai, Ankur Jindal, and Amar Mukund final approval of the version to be published.
<i>QuickStats:</i> Percentage* of Adults Who Received Any Mental Health Treatment in the Past 12 Months,† by Age Group and Year — National Health Interview Survey, United States, 2019–2020§
Authors: Emily Terlizzi, Tina Norris
Journal: MMWR Morbidity and Mortality Weekly Report (2021)

Age group, yrs * 95% confidence intervals indicated with error bars.† Adults were considered to have received any mental health treatment if they reported having taken prescription medication for their mental health or having received counseling or therapy from a mental health professional in the past 12 months.§ Estimates are based on household interviews of a sample of the civilian, noninstitutionalized U.S. population.The percentage of adults who had received any mental health treatment in the past 12 months increased from 2019 to 2020 overall (19.2% to 20.3%) and among adults aged 18-44 years (18.5% to 20.9%).In 2019, the percentage of adults who had received any mental health treatment in the past 12 months was lower among those aged 18-44 years (18.5%) compared with those aged 45-64 years (20.2%) and ≥65 years (19.4%).In 2020, the percentage decreased with age, from 20.9% among adults aged 18-44 years to 18.7% among those aged ≥65 years.
Assessing the value of a novel MRI protocol in patients undergoing posterior urethroplasty for Pelvic Fracture Urethral Distraction Defect (PFUDD)
Authors: P.M. Joshi, M. Bandini, A. Patil, S. Bhadranavar, S.L. Yatam, V. Sharma, G. Barbagli, F. Montorsi, S.B. Kulkarni
Journal: European Urology (2021)
Factors associated with excess all-cause mortality in the first wave of the COVID-19 pandemic in the UK: A time series analysis using the Clinical Practice Research Datalink
Authors: Helen Strongman, Helena Carreira, Bianca L. De Stavola, Krishnan Bhaskaran, David A. Leon
Journal: PLoS Medicine (2022)

Excess mortality captures the total effect of the Coronavirus Disease 2019 (COVID-19) pandemic on mortality and is not affected by misspecification of cause of death. We aimed to describe how health and demographic factors were associated with excess mortality during, compared to before, the pandemic.We analysed a time series dataset including 9,635,613 adults (≥40 years old) registered at United Kingdom general practices contributing to the Clinical Practice Research Datalink. We extracted weekly numbers of deaths and numbers at risk between March 2015 and July 2020, stratified by individual-level factors. Excess mortality during Wave 1 of the UK pandemic (5 March to 27 May 2020) compared to the prepandemic period was estimated using seasonally adjusted negative binomial regression models. Relative rates (RRs) of death for a range of factors were estimated before and during Wave 1 by including interaction terms. We found that all-cause mortality increased by 43% (95% CI 40% to 47%) during Wave 1 compared with prepandemic. Changes to the RR of death associated with most sociodemographic and clinical characteristics were small during Wave 1 compared with prepandemic. However, the mortality RR associated with dementia markedly increased (RR for dementia versus no dementia prepandemic: 3.5, 95% CI 3.4 to 3.5; RR during Wave 1: 5.1, 4.9 to 5.3); a similar pattern was seen for learning disabilities (RR prepandemic: 3.6, 3.4 to 3.5; during Wave 1: 4.8, 4.4 to 5.3), for black or South Asian ethnicity compared to white, and for London compared to other regions. Relative risks for morbidities were stable in multiple sensitivity analyses. However, a limitation of the study is that we cannot assume that the risks observed during Wave 1 would apply to other waves due to changes in population behaviour, virus transmission, and risk perception.The first wave of the UK COVID-19 pandemic appeared to amplify baseline mortality risk to approximately the same relative degree for most population subgroups. However, disproportionate increases in mortality were seen for those with dementia, learning disabilities, non-white ethnicity, or living in London.
The PROFILE study. Targeted screening using germline genetics in men with a family history of prostate cancer
Authors: H. Ni Raghallaigh, M.N. Brook, E.J. Saunders, P. Kumar, S. Hazell, A. Sohaib, A. Dias, E. Mcgrowder, S. Wakerell, K. Myhill, N. Taylor, D. James, M. Hogben, J. Offman, N. Desouza, E. Bancroft, Z. Kote-Jarai, R. Eeles
Journal: European Urology (2021)
Current Medical Literature.
Journal: JAMA (1905)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal